Does discontinuation of RAASi after hyperkalemia worsen mortality and cardiorenal outcomes in patients with CKD?
Discontinuing RAAS inhibitors following a hyperkalemia event in patients with CKD is associated with increased mortality, highlighting the potential benefit of maintaining RAASi therapy.
RAASi discontinuation after hyperkalemia was associated with worsened mortality, which may underscore the benefits of continuing RAASi among patients with CKD.
An et al. (Sun,) studied this question.